DOI:
10.1055/s-00000020
Geburtshilfe und Frauenheilkunde
LinksClose Window
References
Gelmon KA, Tischkowitz M, Mackay H. et al.
Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.
Lancet Oncol 2011;
12: 852-861
DOI: 10.1016/S1470-2045(11)70214-5.
We do not assume any responsibility for the contents of the web pages of other providers.